OVOL1 and cancer: Interestingly, these TFs, together with OVOL1/2 (Ovo Like Transcriptional Repressors 1 and 2), had previously been suspected to inhibit epithelial–mesenchymal transition in cancer cells [54,55] with a hierarchically dominant position for GRHL2, which directly induces expression of EHF and OVOL2 [56,57] (Fig 5B).